A meta-analysis of randomized controlled trials concluded that colchicine treatment may reduce the risk of cardiovascular events in patients with coronary artery disease (CAD). The analysis included 5 randomized controlled trials with follow-up duration ≥6 months, comprising a total of 11,790 patients with CAD. Compared with placebo or no treatment, colchicine treatment was associated with a significantly lower incidence of major cardiovascular events (relative risk [RR] 0.65). Such a benefit was not modified by the clinical phenotype of CAD (p for interaction = 0.34). Colchicine treatment also decreased the risk of myocardial infarction (RR 0.73), coronary revascularization (RR 0.61) and stroke (RR 0.47) in CAD patients, but with no impact on cardiovascular mortality. In addition, the rates of common adverse events were generally similar between colchicine and control groups, including non-cardiovascular deaths (RR 1.50) and gastrointestinal symptoms (RR 1.05). The benefits of colchicine may be due to its broad anti-inflammatory properties. Source: https://www.ajconline.org/
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2…
A new study investigating the link between cerebral microbleeds (CMBs) and dementia has found that…
A comprehensive prospective study tracking over 159,000 adults for up to three decades has provided…
A comprehensive new Cochrane review of 22 studies involving nearly 2,000 participants over six months…
A large-scale study involving 103,649 UK Biobank participants has revealed that adhering to healthy dietary…
To address uncertainties in statin safety profiles, which are often based on observational data susceptible…
This website uses cookies.